Multiple sclerosis patients and immunomodulation therapies: The potential role of new MRI techniques to assess responders versus non-responders

Neurological Sciences

Volumn 26, Issue SUPPL. 4, 2005, Pages

  Tedeschi, Gioacchino ^a   Gallo, A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Immunomodulation therapy; MRI; Multiple sclerosis; Responders

Indexed keywords

BETA INTERFERON; IMMUNOMODULATING AGENT;

ACCURACY; ARTICLE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; GENETIC HETEROGENEITY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSE; RELIABILITY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTONS; TREATMENT OUTCOME;

EID: 30644473905     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0516-4     Document Type: Article

References (29)

1. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45:1277-1285
2. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of the phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
3. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
4. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
5. Petereit HF, Nolden S, Schoppe S et al (2002) Low interferon gamma producers are better treatment responders: A two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 8:492-494
6. Killestein J, Hintzen RQ, Uitdehaag BM et al (2002) Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J Neuroimmunol 133:217-224
7. Wandinger KP, Lunemann JD, Wengert O et al (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361:2036-2043
8. Waubant E, Vukusic S, Gignoux L et al (2003) Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61:184-189
9. Giovannoni G, Munschauser FE 3rd, Deisenhammer F (2002) Neutralizing antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:465-469
10. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISM-4: Longterm efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628-1636
11. Van Waesberghe JHTM, Kamphorst W, De Groot C et al (1999) Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754
12. Dousset V, Gayou A, Brochet B, Caillé JM (1998) Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology 51:1150-1155
13. Filippi M, Iannucci G, Tortorella C et al (1999) Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 52:588-594
14. Ge Y, Grossman RI, Udupa JK et al (2002) Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis. J Comput Assist Tomogr 26:62-68
15. Allen IV, McKeown SR (1979) A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41:81-89
16. Filippi M, Dousset V, McFarland HF et al (2002) The role of MRI in the diagnosis and monitoring of multiple sclerosis. Consensus report of the "White Matter Study Group" of the International Society for Magnetic Resonance in Medicine. J Magn Reson Imaging 15:499-504
17. Richert ND, Ostuni JL, Bash CN et al (1998) Serial wholebrain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 19:1705-1713
18. Kita M, Goodkin DE, Bacchetti P et al (2000) Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a. Neurology 54:1741-1745
19. Pierpaoli C, Jezzard P, Basser PJ et al (1996) Diffusion tensor MR imaging of the human brain. Radiology 201:637-648
20. Werring DJ, Clark CA, Barker GJ et al (1999) Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 52:1626-1632
21. Cercignani M, Bozzali M, Iannucci G et al (2001) Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 70:311-317
22. Moffett JR, Namboodiri MAA, Cangro CB, Neale JH (1991) Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2:131-134
23. De Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34:721-727
24. Arnold DL, Matthews PM, Francis GS et al (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31:235-241
25. Tedeschi G, Bonavita S, McFarland HF et al (2002) Proton MR spectroscopic imaging in multiple sclerosis. Neuroradiology 44:37-42
26. De Stefano N, Matthews PM, Fu L et al (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469-1477
27. Rocca MA, Falini A, Colombo B et al (2002) Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol 51:330-339
28. Staffen W, Mair A, Zauner H et al (2002) Cognitive function and fMRI in patients with multiple sclerosis: Evidence for compensatory cortical activation during an attention task. Brain 125:1275-1282
29. Rocca MA, Matthews PM, Caputo D et al (2002) Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 58:866-872